Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Sep;29(3):376–384.

Transfer factor therapy in ataxia--telangiectasia.

A I Berkel, F Ersoy, L B Epstein, L E Spitler
PMCID: PMC1541059  PMID: 201409

Abstract

The effects of weekly doses of transfer factor in four patients with ataxia--telangiectasia were investigated following a total course of 2 months therapy. Transfer factor administration showed no influence on the absolute lymphocyte counts, T-cell rosettes or antibody titres to EBV, but it caused conversion of skin-test reactivity and production of MIF to various antigens. There was a dissociation in blastic transformation response, the skin-test responses and MIF production. Serum interferon levels were low before, and 2, 6 and 24 hr after, therapy. Clinically no improvement in infections was observed following transfer factor therapy.

Full text

PDF
376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August C. S., Merler E., Lucas D. O., Janeway C. A. The response in vitro of human lymphocytes to phytohemagglutinin and to antigens after fractionation on discontinuous density gradients of albumin. Cell Immunol. 1970 Dec;1(6):603–618. doi: 10.1016/0008-8749(70)90026-2. [DOI] [PubMed] [Google Scholar]
  2. Bach F. H., Voynow N. K. One-way stimulation in mixed leukocyte cultures. Science. 1966 Jul 29;153(3735):545–547. doi: 10.1126/science.153.3735.545. [DOI] [PubMed] [Google Scholar]
  3. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig Artic Ser. 1975;11(1):255–270. [PubMed] [Google Scholar]
  4. Emödi G., Just M., Grob P. Letter: Circulating interferon after transfer-factor therapy. Lancet. 1973 Dec 15;2(7842):1382–1382. doi: 10.1016/s0140-6736(73)93340-0. [DOI] [PubMed] [Google Scholar]
  5. Ersoy F., Berkel A. I. Clinical and immunological studies in twenty families with ataxia-telangiectasia. Turk J Pediatr. 1974 Oct;16(4):145–160. [PubMed] [Google Scholar]
  6. FAHEY J. L., MCKELVEY E. M. QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES. J Immunol. 1965 Jan;94:84–90. [PubMed] [Google Scholar]
  7. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Henle G., Henle W., Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer. 1971 Sep 15;8(2):272–282. doi: 10.1002/ijc.2910080212. [DOI] [PubMed] [Google Scholar]
  9. Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jose D. G., Ford G. W. Therapy with parent's lymphocyte transfer factor in children with infection and malnutrition. Lancet. 1976 Feb 7;1(7954):263–266. doi: 10.1016/s0140-6736(76)91399-4. [DOI] [PubMed] [Google Scholar]
  11. Kirkpatrick C. H., Smith T. K. Chronic mucocutaneous candidiasis: immunologic and antibiotic therapy. Ann Intern Med. 1974 Mar;80(3):310–320. doi: 10.7326/0003-4819-80-3-310. [DOI] [PubMed] [Google Scholar]
  12. Levin A. S., Byers V. S., Fudenberg H. H., Wybran J., Hackett A. J., Johnston J. O. Transfer factor therapy in osteogenic sarcoma. Trans Assoc Am Physicians. 1974;87:153–158. [PubMed] [Google Scholar]
  13. Levin A. S., Spitler L. E., Fudenberg H. H. Transfer factor I: methods of therapy. Birth Defects Orig Artic Ser. 1975;11(1):445–448. [PubMed] [Google Scholar]
  14. Rytel M. W., Aaberg T. M., Dee T. H., Heim L. H. Therapy of cytomegalovirus retinitis with transfer factor. Cell Immunol. 1975 Sep;19(1):8–21. doi: 10.1016/0008-8749(75)90287-7. [DOI] [PubMed] [Google Scholar]
  15. Spitler L. E., Levin A. S., Fudenberg H. H. Transfer factor II: results of therapy. Birth Defects Orig Artic Ser. 1975;11(1):449–456. [PubMed] [Google Scholar]
  16. Spitler L. E., Levin A. S., Stites D. P., Fudenberg H. H., Pirofsky B., August C. S., Stiehm E. R., Hitzig W. H., Gatti R. A. The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest. 1972 Dec;51(12):3216–3224. doi: 10.1172/JCI107148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Spitler L. E., Levin A. S., Wybran J. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin. Cell Immunol. 1976 Jan;21(1):1–19. doi: 10.1016/0008-8749(76)90322-1. [DOI] [PubMed] [Google Scholar]
  18. Valdimarsson H., Wood C. B., Hobbs J. R., Holt P. J. Immunological features in a case of chronic granulomatous candidiasis and its treatment with transfer factor. Clin Exp Immunol. 1972 Jun;11(2):151–163. [PMC free article] [PubMed] [Google Scholar]
  19. Vandvik B., Froland S. S., Hoyeraal H. M., Stien R., Degré M. Immunological features in a case of subacute sclerosing panencephalitis treated with transfer factor. Scand J Immunol. 1973;2(4):367–374. doi: 10.1111/j.1365-3083.1973.tb02045.x. [DOI] [PubMed] [Google Scholar]
  20. Vetto R. M., Burger D. R., Nolte J. E., Vandenbark A. A., Baker H. W. Transfer factor therapy in patients with cancer. Cancer. 1976 Jan;37(1):90–97. doi: 10.1002/1097-0142(197601)37:1<90::aid-cncr2820370113>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  21. Whitcomb M. E., Rocklin R. E. Transfer factor therapy in a patient with progressive primary tuberculosis. Ann Intern Med. 1973 Aug;79(2):161–166. doi: 10.7326/0003-4819-79-2-161. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES